<DOC>
	<DOCNO>NCT02668796</DOCNO>
	<brief_summary>This Randomized , Parallel-Group , Placebo- Controlled , Multicenter Study Evaluate Therapeutic Equivalence Safety Estradiol Vaginal Tablets 10 mcg Vagifem® ( Estradiol Vaginal Tablets ) 10 mcg ( Novo Nordisk Inc. ) Female Subjects Moderate Severe Symptoms Vulvar Vaginal Atrophy Associated Menopause .</brief_summary>
	<brief_title>To Study Generic Estradiol 10 mcg Vaginal Tablets Treatment Vulvar Vaginal Atrophy Post Menopausal Women .</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Female postmenopausal subject age &gt; 30 &lt; 75 year 2 . At least 1 subject assess moderate severe symptom vulvar vaginal atrophy among follow identify bothersome vaginal dryness vaginal and/or vulvar irritation/ itch dysuria vaginal pain associate sexual activity presence vaginal bleeding associate sexual activity 3 . Have &lt; 5 % superficial cell vaginal smear cytology vaginal pH &gt; 5.0 Visit 1 4 . Systolic blood pressure &lt; 150mm Hg diastolic blood pressure &lt; 90mm Hg Visit 1 1 . Known hypersensitivity Estradiol vaginal tablet 2 . Screening mammogram clinical breast examination result indicate suspicion breast malignancy . 3 . History undiagnosed vaginal bleeding . 4 . History significant risk factor endometrial cancer 5 . For woman intact uterus , screen vaginal ultrasonography show endometrial thickness ≥ 4 mm .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>